p63

Prostate tissue stained with p63 antibody

p53 homologue p63 encodes for different isotypes able to either transactivate p53 reporter genes (TAp63) or act as p53-dominant-negatives. p63 is detected in prostatic basal cells in normal prostate; however, it is negative in malignant tumors of the prostate gland. Thus p63 antibody may be a valuable tool in the differential diagnosis of benign and malignant tumors of prostate gland and can be used in a panel of antibodies such as HMW CK [34ßE12], PSA and PSAP. p63 may play a significant role in prostate development by maintaining a prostate stem cell population. Striated muscle staining may be observed with p63.

p63, 2X (Lung)

Lung SqCC stained with p63, 2X

p63 has been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with reported sensitivities of 80-100% (1-6). Specificity for lung SqCC, versus lung adenocarcinoma (LADC), has been reported to be approximately 70-90%, as positive staining with p63 has been typically observed in 10-30% of LADC (1-6). Cocktails of p63 with complementary markers for lung SqCC have also proven useful. A cocktail of p63 + TRIM29 demonstrated a 94.7% sensitivity for lung SqCC and 100% specificity versus LADC, in cases where Napsin A and TTF-1 were both negative (2-7). Similarly, the combination of p63 + CK5 identified 87% of cases of lung SqCC, with 94% specificity (8).

p63, 3X (Breast)

Breast cancer stained with p63 antibody

p63, 3X (Breast) [4A4] is comprised of a mouse monoclonal anti-p63 antibody. p63 is a transcription factor present in the nuclei of myoepithelial cells of normal breast ducts (1,2). p63 has routinely been used in a panel of IHC markers to complement morphological evaluation in the assessment of breast lesions, due to the differential expression of the luminal vs. basal and myoepithelial markers (1-6). Cases of usual ductal hyperplasia (UDH) have been associated with expression of the basal cell markers, intermixed with cells expressing the keratins of luminal cells (1-3,7-11). Most cases of atypical ductal hyperplasia (ADH) and low grade ductal carcinoma in situ (LG DCIS) were negative for basal markers and exhibited an immunophenotype indicative of luminal cells (1,5-9). Additionally, the basal phenotype has been shown to be characterized by luminal expression of the basal and myoepithelial markers, using a cocktail of CK5, CK14 and p63 (12-14).
IHC, using CK5, CK14, p63, CK7 and CK18 antibodies, evaluated in combination with hematoxylin and eosin (H&E), has been shown to significantly increase interobserver agreement amongst pathologists, compared to H&E alone (15).

p63, 3X (Breast)

Breast cancer stained with p63 antibody

p63, 3X (Breast) Antibody [4A4] is comprised of a mouse monoclonal anti-p63 antibody. p63 is a transcription factor present in the nuclei of myoepithelial cells of normal breast ducts (1,2). p63 has routinely been used in a panel of IHC markers to complement morphological evaluation in the assessment of breast lesions, due to the differential expression of the luminal vs. basal and myoepithelial markers (1-6). Cases of usual ductal hyperplasia (UDH) have been associated with expression of the basal cell markers, intermixed with cells expressing the keratins of luminal cells (1-3,7-11). Most cases of atypical ductal hyperplasia (ADH) and low grade ductal carcinoma in situ (LG DCIS) were negative for basal markers and exhibited an immunophenotype indicative of luminal cells (1,5-9). Additionally, the basal phenotype has been shown to be characterized by luminal expression of the basal and myoepithelial markers, using a cocktail of CK5, CK14 and p63 (12-14).

IHC, using CK5, CK14, p63, CK7 and CK18 antibodies, evaluated in combination with hematoxylin and eosin (H&E), has been shown to significantly increase interobserver agreement amongst pathologists, compared to H&E alone (15).

 

p63, 3X (Breast)

Breast cancer stained with p63, 3X

p63, 3X (Breast) Antibody [4A4] is comprised of a mouse monoclonal anti-p63 antibody. p63 is a transcription factor present in the nuclei of myoepithelial cells of normal breast ducts
(1,2). p63 has routinely been used in a panel of IHC markers to complement morphological evaluation in the assessment of breast lesions, due to the differential expression of the luminal vs. basal and myoepithelial markers (1-6). Cases of usual ductal hyperplasia (UDH) have been associated with expression of the basal cell markers, intermixed with cells expressing the keratins of luminal cells (1-3,7-11). Most cases of atypical ductal hyperplasia (ADH) and low grade ductal carcinoma in situ (LG DCIS) were negative for basal markers and exhibited an immunophenotype indicative of luminal cells (1,5-9). Additionally, the basal phenotype has been shown to be characterized by luminal expression of the basal and myoepithelial markers, using a cocktail of CK5, CK14 and p63 (12-14).

IHC, using CK5, CK14, p63, CK7 and CK18 antibodies, evaluated in combination with hematoxylin and eosin (H&E), has been shown to significantly increase interobserver agreement amongst pathologists, compared to H&E alone (15).

p63, 3X (Prostate)

Prostate tissue stained with p63 prostate antibody, 3X

p63, a homolog of the tumor suppressor p53, has been identified in proliferating basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; and prostatic intraepithelial neoplasia (PIN); however, it was not expressed in malignant tumors of the prostate.

p63-2X

Prostate cancer stained with p63 [4a4] antibody, 2X

p53 homologue p63 encodes for different isotypes able to either transactivate p53 reporter genes (TAp63) or act as p53-dominant-negatives. Studies have shown that p63 [4a4] antibody detection by IHC has clinical utility in the evaluation of lung, prostate, cervical and other types of cancer in formalin fixed, paraffin-embedded (FFPE) human tissues. A cocktail of p63 and TRIM29 can also be utilized for lung SqCC and studies have shown that when p63 and/or TRIM29 is expressed in lung SqCC, a 95.4% sensitivity and 100% specificity was achieved, if Napsin A and TTF-1 were both negative in the same case.